{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:05:02Z","timestamp":1789625102418,"version":"build-2803163510"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Dipeptidyl peptidase-4 inhibitors and thiazolidinediones are commonly used as add-ons in type 2 diabetes mellitus (T2DM) treatment, but comparative data are limited. This study emulated a target trial to compare sitagliptin and pioglitazone in patients on metformin and sulfonylurea, focusing on changes in glycemic control and clinical outcomes. This emulated target trial comprised 68,372 patients with T2DM identified from 4 university hospitals in South Korea (2001\u20132024). Patients with T2DM receiving both metformin and sulfonylurea were included and assigned to groups receiving either pioglitazone or sitagliptin as add-on therapy using 1:1 propensity score matching. Clinical indicators, including glycemic parameters, were evaluated for differences between groups using unpaired t-tests during the 24-week follow-up. To assess the possibility of achieving intensive glycemic control (HbA1c\u2005&lt;\u20056.5%), Cox proportional hazards analysis was performed, reporting adjusted hazard ratio (aHR) with 95% confidence intervals (CIs). Following 1:1 propensity score matching, 1742 participants were assigned to each of the pioglitazone (mean age, 58.75 years; 64.7% male) and sitagliptin (mean age, 58.95 years; 64.7% male) groups. Both pioglitazone and sitagliptin reduced HbA1c over 24 weeks with no significant between-group difference (pioglitazone: \u22120.48% [95% CI, \u22120.55 to \u22120.41]; sitagliptin: \u22120.55% [95% CI, \u22120.61 to \u22120.48];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      -value\u2005=\u2005.182 for the between-group difference). However, sitagliptin was associated with a higher possibility of achieving HbA1c\u2005&lt;\u20056.5% (aHR, 1.28 [95% CI, 1.08\u20131.53]), and showed greater reductions in body weight (pioglitazone: 0.26\u2009kg [95% CI, \u22120.37 to 0.89]; sitagliptin: \u22120.91\u2009kg [95% CI, \u22121.65 to \u22120.17];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      -value\u2005=\u2005.018 for the between-group difference) and LDL cholesterol (pioglitazone: \u22122.22 mmol\/L [95% CI, \u22127.41 to 2.96]; sitagliptin: \u221211.42 mmol\/L [95% CI, \u221216.95 to \u22125.89];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      -value\u2005=\u2005.017 for the between-group difference). Our findings suggest that sitagliptin showed more favorable metabolic profiles and a higher likelihood of achieving intensive glycemic targets compared with pioglitazone, beyond average glycemic control.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050241","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:04:36Z","timestamp":1787331876000},"page":"e50241","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness of pioglitazone and sitagliptin added to metformin and sulfonylurea in patients with type 2 diabetes"],"prefix":"10.1097","volume":"105","author":[{"given":"Tae Hyeon","family":"Kim","sequence":"first","affiliation":[{"name":"Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea"},{"name":"Department of Precision Medicine, Kyung Hee University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yerin","family":"Hwang","sequence":"additional","affiliation":[{"name":"Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea"},{"name":"Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selin","family":"Woo","sequence":"additional","affiliation":[{"name":"Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea"},{"name":"Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeongmin","family":"Lee","sequence":"additional","affiliation":[{"name":"Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea"},{"name":"Department of Regulatory Science, Kyung Hee University, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yejun","family":"Son","sequence":"additional","affiliation":[{"name":"Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea"},{"name":"Department of Precision Medicine, Kyung Hee University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoyoung","family":"Park","sequence":"additional","affiliation":[{"name":"Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea"},{"name":"Department of Precision Medicine, Kyung Hee University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunjee","family":"Kim","sequence":"additional","affiliation":[{"name":"Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea"},{"name":"Department of Precision Medicine, Kyung Hee University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YongHyun","family":"Cho","sequence":"additional","affiliation":[{"name":"RWE Division, Kakao Healthcare Corp., Seongnam, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahye","family":"Shin","sequence":"additional","affiliation":[{"name":"RWE Division, Kakao Healthcare Corp., Seongnam, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dosang","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, College of Medicine, Ewha Womans University, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Jae","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Keimyung University Dongsan Hospital, Daegu, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Surgery, Chonnam National University Hwasun Hospital and Medical School, Hwasun, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Youl","family":"Rhee","sequence":"additional","affiliation":[{"name":"Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea"},{"name":"Department of Precision Medicine, Kyung Hee University College of Medicine, Seoul, South Korea"},{"name":"Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea"},{"name":"Department of Endocrinology and Metabolism, Kyung Hee University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1628-9948","authenticated-orcid":false,"given":"Dong Keon","family":"Yon","sequence":"additional","affiliation":[{"name":"Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea"},{"name":"Department of Precision Medicine, Kyung Hee University College of Medicine, Seoul, South Korea"},{"name":"Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea"},{"name":"Department of Regulatory Science, Kyung Hee University, Seoul, South Korea"},{"name":"Department of Pediatrics, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260917","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","article-title":"Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy.","volume":"9","author":"Lu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"Supplement_1","key":"R2-20260917","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025.","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"R3-20260917","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.2337\/dc21-0529","article-title":"Prescribing trends of antidiabetes medications in patients with type 2 diabetes and diabetic kidney disease, a cohort study.","volume":"44","author":"Harris","year":"2021","journal-title":"Diabetes Care"},{"key":"R4-20260917","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.2337\/dc22-0224","article-title":"Trends in prescribing preferences for antidiabetic medications among patients with type 2 diabetes in the U.K. with and without chronic kidney disease, 2006-2020.","volume":"45","author":"Liaw","year":"2022","journal-title":"Diabetes Care"},{"key":"R5-20260917","first-page":"1253","article-title":"Trends in add-on medications following metformin monotherapy for type 2 diabetes.","volume":"28","author":"Swart","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"R6-20260917","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3109\/07853890.2016.1157263","article-title":"Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.","volume":"48","author":"Mamza","year":"2016","journal-title":"Ann Med"},{"key":"R7-20260917","doi-asserted-by":"crossref","first-page":"e70588","DOI":"10.1002\/mco2.70588","article-title":"Loss of beta-cell identity and function as a mechanism of secondary failure of sulfonylurea therapy in diabetes.","volume":"7","author":"Patel","year":"2026","journal-title":"MedComm (2020)"},{"key":"R8-20260917","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2337\/diacare.28.5.995","article-title":"Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes.","volume":"28","author":"Cook","year":"2005","journal-title":"Diabetes Care"},{"key":"R9-20260917","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","article-title":"Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.","volume":"16","author":"Deacon","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"R10-20260917","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cmet.2014.08.005","article-title":"Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.","volume":"20","author":"Soccio","year":"2014","journal-title":"Cell Metab"},{"key":"R11-20260917","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12933-021-01294-7","article-title":"Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug.","volume":"20","author":"Nesti","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"R12-20260917","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2337\/dc11-1107","article-title":"Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.","volume":"35","author":"Russell-Jones","year":"2012","journal-title":"Diabetes Care"},{"key":"R13-20260917","doi-asserted-by":"crossref","first-page":"980","DOI":"10.4158\/EP13148.OR","article-title":"Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.","volume":"19","author":"Liu","year":"2013","journal-title":"Endocr Pract"},{"key":"R14-20260917","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40618-018-0991-0","article-title":"Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea.","volume":"42","author":"Khaloo","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"R15-20260917","doi-asserted-by":"crossref","first-page":"e181755","DOI":"10.1001\/jamanetworkopen.2018.1755","article-title":"Association of hemoglobin A1c levels with use of sulfonylureas, dipeptidyl peptidase 4 inhibitors, and thiazolidinediones in patients with type 2 diabetes treated with metformin: analysis from the observational health data sciences and informatics initiative.","volume":"1","author":"Vashisht","year":"2018","journal-title":"JAMA Netw Open"},{"key":"R16-20260917","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/jamia\/ocac158","article-title":"Translating and evaluating historic phenotyping algorithms using SNOMED CT.","volume":"30","author":"Elkheder","year":"2023","journal-title":"J Am Med Inform Assoc"},{"key":"R17-20260917","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/dom.12055","article-title":"Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial.","volume":"15","author":"Takihata","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"R18-20260917","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12933-023-01875-8","article-title":"Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions.","volume":"22","author":"Chen","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"R19-20260917","doi-asserted-by":"crossref","first-page":"e077664","DOI":"10.1136\/bmj-2023-077664","article-title":"Prenatal opioid exposure and subsequent risk of neuropsychiatric disorders in children: nationwide birth cohort study in South Korea.","volume":"385","author":"Kang","year":"2024","journal-title":"BMJ"},{"key":"R20-20260917","doi-asserted-by":"crossref","first-page":"e14114","DOI":"10.1111\/pai.14114","article-title":"Prenatal and postnatal exposure to antibiotics and risk of food allergy in the offspring: a nationwide birth cohort study in South Korea.","volume":"35","author":"Oh","year":"2024","journal-title":"Pediatr Allergy Immunol"},{"key":"R21-20260917","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1038\/s41467-024-48825-w","article-title":"Acute and post-acute respiratory complications of SARS-CoV-2 infection: population-based cohort study in South Korea and Japan.","volume":"15","author":"Choi","year":"2024","journal-title":"Nat Commun"},{"key":"R22-20260917","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/dom.13018","article-title":"Do we know the true mechanism of action of the DPP-4 inhibitors?","volume":"20","author":"Andersen","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R23-20260917","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/dom.12128","article-title":"Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.","volume":"16","author":"Liu","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"R24-20260917","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"R25-20260917","doi-asserted-by":"crossref","first-page":"173037","DOI":"10.1016\/j.ejphar.2020.173037","article-title":"The protective role of DPP4 inhibitors in atherosclerosis.","volume":"875","author":"Liu","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"R26-20260917","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bioorg.2018.02.009","article-title":"Thiazolidinediones as antidiabetic agents: a critical review.","volume":"77","author":"Nanjan","year":"2018","journal-title":"Bioorg Chem"},{"key":"R27-20260917","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack.","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"R28-20260917","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13098-017-0290-5","article-title":"Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis.","volume":"9","author":"Filipova","year":"2017","journal-title":"Diabetol Metab Syndr"},{"key":"R29-20260917","doi-asserted-by":"crossref","first-page":"465","DOI":"10.4093\/dmj.2013.37.6.465","article-title":"Glycemic effectiveness of metformin-based dual-combination therapies with sulphonylurea, pioglitazone, or DPP4-inhibitor in drug-na\u00efve Korean type 2 diabetic patients.","volume":"37","author":"Lee","year":"2013","journal-title":"Diabetes Metab J"},{"key":"R30-20260917","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2337\/dc17-0636","article-title":"The fallacy of average: how using HbA(1c) alone to assess glycemic control can be misleading.","volume":"40","author":"Beck","year":"2017","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"R31-20260917","first-page":"S83","article-title":"6. Glycemic targets: standards of medical care in diabetes-2022.","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"R32-20260917","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1210\/endrev\/bnad030","article-title":"Protective factors and the pathogenesis of complications in diabetes.","volume":"45","author":"Yu","year":"2024","journal-title":"Endocr Rev"},{"key":"R33-20260917","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.orcp.2024.02.006","article-title":"Associations of overweight and obesity with the risk of cardiovascular disease according to metabolic risk factors among middle-aged Japanese workers: the Aichi Workers\u2019 cohort study.","volume":"18","author":"Al-Shoaibi","year":"2024","journal-title":"Obes Res Clin Pract"},{"key":"R34-20260917","doi-asserted-by":"crossref","first-page":"3819830","DOI":"10.1155\/2023\/3819830","article-title":"Association of obesity indices with diabetic kidney disease and diabetic retinopathy in type 2 diabetes: a real-world study.","volume":"2023","author":"Shi","year":"2023","journal-title":"J Diabetes Res"},{"key":"R35-20260917","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13643-023-02321-2","article-title":"Relationship between dyslipidemia and diabetic retinopathy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.","volume":"12","author":"Li","year":"2023","journal-title":"Syst Rev"},{"key":"R36-20260917","doi-asserted-by":"crossref","first-page":"e016947","DOI":"10.1161\/JAHA.120.016947","article-title":"Metabolic dyslipidemia and cardiovascular outcomes in type 2 diabetes mellitus: findings from the look AHEAD study.","volume":"10","author":"Kaze","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"R37-20260917","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.2215\/CJN.08310520","article-title":"Higher-dose sitagliptin and the risk of congestive heart failure in older adults with CKD.","volume":"15","author":"Muanda","year":"2020","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:00:49Z","timestamp":1789624849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050241"}},"subtitle":["An emulated target trial"],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":37,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050241","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"2025-10-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}